UPDATE: Sarepta Therapeutics (SRPT) Posts Wider-than-Expected Q2 Loss

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.35), versus the analyst estimate of ($1.23).

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• Stifel Starts Victrex Plc. (VCT:LN) (VTXPF) at Buy